[New aspects in thyroid cancer treatment : Highlights of the ASCO Annual Meeting 2018].
Authors of this article are:
Möckelmann N, Münscher A.
A summary of the article is shown below:
Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected and analyzed. Clinically and preclinically relevant studies are presented and critically interpreted in this review.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as:
Anaplastic;Immunotherapy;Radioiodine-refractory;Thyroid cancer;Tyrosine kinase inhibitor
Categories: Science News